The Warrant. Certificates for the Warrants shall be issued in registered form only. The text of the Warrant Certificate, including the form of assignment and subscription printed on the reverse side thereof, shall be substantially in the form of Exhibit A annexed hereto, which text is hereby incorporated in this Agreement by reference as though fully set forth herein and to whose terms and conditions the Company and the Warrant Agent hereby agree. Each Warrant Certificate shall evidence the right, subject to the provisions of this Agreement and of such Warrant Certificate, to purchase the number of validly issued, fully paid and non-assessable shares of Common Stock, as that term is defined in Section 1.05 of this Agreement, stated therein, free of preemptive rights, subject to adjustment as provided in Article III of this Agreement.
The Warrant. This Warrant and the rights and privileges of the Holder hereunder may be exercised by the Holder in whole or in part as provided herein, shall survive any termination of the Credit Agreement and, as more fully set forth in Sections 1(b) and 7 hereof, subject to the terms of this Warrant, may be transferred by the Holder to any other Person or Persons who meet the requirements set forth herein at any time or from time to time, in whole or in part, regardless of whether the Holder retains any or all rights under the Credit Agreement.
The Warrant. On the Subscription Date, the Company shall issue the Warrant to the Investor. The Warrant shall be delivered by the Company to the Investor upon execution of this Agreement by the parties hereto. The Warrant Shares shall be registered for resale pursuant to the Registration Rights Agreement.
The Warrant. On the Closing Date, the Company will issue to the Investor a warrant exercisable beginning six months from the Subscription Date and then exercisable any time over the three-year period there following, to purchase the Investor's pro-rata share of an aggregate of 50,000 Warrant Shares at the Exercise Price (as defined in the Warrant) in the form of Exhibit B hereto. The Warrant Shares shall be registered for resale pursuant to the Registration Rights Agreement.
The Warrant. At the Closing, the Company shall issue to the Purchaser, a Common Stock purchase warrant, in the form of Exhibit D (the "Warrant"), pursuant to which the Purchaser shall have the right at any time and from time to time thereafter through the second anniversary of the date of issuance thereof, to acquire 60,000 shares of Common Stock at an exercise price per share equal to 110% of the Average Price on the Closing Date.
The Warrant. The Company hereby grants to the Holder a warrant attached hereto as Annex A (the “Warrant”) to purchase up to an aggregate of 5,500,000 post-split shares of the Class A Common Stock, $0.001 par value, of the Company (the “Common Stock”), at an exercise price of $0.001 per share. The shares of fully paid, duly authorized and non-assessable Common Stock issuable upon exercise of the Warrant are referred herein as the “Warrant Shares.” The number of shares of common stock to be acquired pursuant to the Warrant represents shares after the Company’s planned 1-for-300 reverse stock split to be effective on or about November 8, 2006. b.
The Warrant. This Warrant is issued under and pursuant to the terms of that certain agreement dated October 15, 1997 (the "Agreement") entered into by the Company and BCF, and this Warrant and the holders hereof are entitled to the benefits provided for by, or referred to in, and are subject to the terms of, the Agreement.
The Warrant. (a) The Company hereby agrees to issue and sell to NovaQuest, its designee or assigns (the “Holder”) 80,000 shares (the “Warrant Shares”) of the Company’s Common Stock, $0.0005 par value per share (“Common Stock”), at an exercise price of One Dollar and Ninety-One Cents ($1.91) per share (the “Exercise Price”) (such Exercise Price was calculated as follows: the average of the closing prices of the shares of Common Stock for the 15 trading days prior to the Restatement Date, multiplied by 115%), upon the terms and conditions herein set forth, including the vesting schedule set forth in this Section 1. The Exercise Price and the number of Warrant Shares purchasable upon exercise of this Warrant Agreement are subject to adjustment from time to time as provided in Section 4 of this Warrant Agreement.
The Warrant. (a) The Company hereby agrees to issue and sell to PharmaBio, its designee or assigns (the "Holder") 80,000 shares (the "Warrant Shares") of the Company's Common Stock, $.0005 par value per share ("Common Stock"), at an exercise price of Six Dollars and Thirty-Nine Cents ($6.39) per share (the "Exercise Price") (such Exercise Price was calculated as follows: the average of the closing prices of the shares of Common Stock for the 15 trading days prior to the date hereof, multiplied by 115%), upon the terms and conditions herein set forth, including the vesting schedule set forth in this Section 1. The Exercise Price and the number of Warrant Shares purchasable upon exercise of this Warrant Agreement are subject to adjustment from time to time as provided in Section 4 of this Warrant Agreement.
The Warrant. The Company hereby agrees to issue and sell to the ----------- Holder one million two hundred fifty thousand (1,250,000) shares (the "Warrant Shares") , of the Company's common stock, par value $.01 per share ("Common Stock"), at an exercise price of two and a quarter U.S. dollars ($2.25) per share (the "Exercise Price"), subject to the vesting schedule described in Section 2 and the other provisions of this Warrant Agreement and upon the terms and conditions herein set forth. The Exercise Price and the number of Warrant Shares purchasable upon exercise of this Warrant Agreement are subject to adjustment from time to time as provided in Section 8 of this Warrant Agreement.
